DiogenX

Name: DiogenX
Address: 165 Avenue du Prado, Marseille, Provence-Alpes-Cote d'Azur, France, 13008, Marseille
Telephone: '+45 22 70 50 65

Marseillebiotechnology

About

DiogenX is a preclinical stage biotech company based in Marseille, France, with research facilities in Nice. Founded in 2020, the company focuses on developing innovative biologics for diabetes treatment, specifically targeting the regeneration of insulin-producing beta cells to address Type 1 Diabetes (T1D). The company's lead program, DGX-01, is a first-in-class recombinant protein designed to modulate the Wnt/β-catenin signaling pathway, aiming to regenerate pancreatic beta cells. This approach represents a potential disease-modifying therapy for T1D patients. DiogenX is supported by a group of notable investors, including Boehringer Ingelheim Venture Fund, Roche Venture Fund, and Eli Lilly and Company. The company was co-founded by Patrick Collombat, Jean-Pascal Tranié, and Benjamin Charles, who serves as the CEO.